CNO
CNO Financial Group, Inc.
CNO's fundamentals are mixed, but it looks expensive: trading at 13x earnings, above its usual 9.1x. Analysts expect earnings growth.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CNO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CNO's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNO.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CNO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $28.30 | -51% |
| Fair | 9.1x | $39.72 | -31% |
| Forward | 11x | $57.44 | — |
| Current | 13x | $57.44 | — |
| Expensive | 15x | $66.35 | +16% |
Historical ranges are pointers, not guarantees.
CNO's PE is in its expensive range at 13x. If earnings grow as analysts expect, today's price would be 11x next year's earnings, in its fair range.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CNO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNO's earnings to grow and its profitability to improve, with its revenue holding steady.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CNO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.03 | +15% |
| Q3 2026 | $4.38 | +53% |
| Q2 2026 | $2.91 | +7.4% |
| Q1 2026 | $2.49 | -13% |
| Q4 2025 | $2.23 | -40% |
| Q3 2025 | $2.86 | +15% |
| Q2 2025 | $2.71 | -30% |
| Q1 2025 | $2.86 | -17% |
| Q4 2024 | $3.74 | +55% |
CNO has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CNO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | -8.6% |
| Q2 2026 | $1.3B | +12% |
| Q1 2026 | $1B | +2.5% |
| Q4 2025 | $1.1B | +4.2% |
| Q3 2025 | $1.2B | +5.2% |
| Q2 2025 | $1.2B | +8% |
| Q1 2025 | $1B | -13% |
| Q4 2024 | $1.1B | -6.3% |
CNO's revenue grew through 2024 and has held roughly level since: $1.1B last quarter, down 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +6.6 points |
| Q2 2026 | 12% | +2 points |
| Q1 2026 | 13% | +2.2 points |
| Q4 2025 | 15% | -0.7 points |
| Q3 2025 | 14% | +0.1 points |
| Q2 2025 | 9.8% | -4.2 points |
| Q1 2025 | 10% | +4 points |
| Q4 2024 | 16% | +1.2 points |
CNO has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over CNO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CNO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $242M | +22% |
| Q2 2026 | $156.6M | +7.6% |
| Q1 2026 | $148.8M | +8.9% |
| Q4 2025 | $195.7M | +2.5% |
| Q3 2025 | $197.8M | -14% |
| Q2 2025 | $145.5M | +31% |
| Q1 2025 | $136.7M | +45% |
| Q4 2024 | $191M | +8.1% |
CNO has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CNO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -699K shares |
| 1 year | -4.4% | -4.3M shares |
| 3 years | -18% | -20.2M shares |
| 5 years | -27% | -34.8M shares |
| Available history | -40% | -62.9M shares |
CNO has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $59.5M |
| Q2 2026 | $60.9M |
| Q1 2026 | $73.3M |
| Q4 2025 | $60.2M |
| Q3 2025 | $60.6M |
| Q2 2025 | $100.3M |
| Q1 2025 | $110.3M |
| Q4 2024 | $91.7M |
CNO spent $254M buying back its own shares over the past year, down 30% from the year before.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CNO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.4x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.2x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
CNO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CNO.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CNO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 74.8 | Neutral |
CNO's weekly RSI is 63 (neutral) and its Stochastic is 75 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CNO PE vs Financial Services Sector
| Metric | CNO | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.7% above |
| PE % | 72 | 63 | 9 pts above |
CNO is trading at 13x earnings, in line with the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CNO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $55.0 | 4.5% above |
| 20 week MA | $54.6 | 5.2% above |
| 50 week MA | $48.1 | 19% above |
| 100 week MA | $43.5 | 32% above |
| 200 week MA | $35.4 | 62% above |
CNO has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CNO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $22.8 | +25% |
| 2021 | $22.8 | $24.0 | +5% |
| 2022 | $24.0 | $22.9 | -4.6% |
| 2023 | $22.9 | $27.9 | +22% |
| 2024 | $27.9 | $37.3 | +34% |
| 2025 | $37.3 | $43.3 | +16% |
| 2026 YTD | $43.3 | $57.4 | +33% |
CNO has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.